Skip to content
What FDA's Step Back Means in Building Credibility episode artwork

Feb 3, 2026 19 min

What FDA's Step Back Means in Building Credibility

from Signal and Symptoms Podcast

The FDA stepped back. Now, organizational governance is the only thing standing between innovation and liability. At CES 2026, the FDA officially announced it won't regulate wellness devices or Clinical Decision Support tools—removing approval bottlenecks and accelerating innovation. But this regulatory shift transfers responsibility to healthcare organizations themselves. Who builds the frameworks for data management when there's no FDA requirement? How do health systems justify physician time reviewing continuous patient streams without reimbursement pathways? And where does liability fall in this new landscape? In this episode, Dr. Junaid and Ed tackle the AI governance vacuum, exploring how healthcare AI agents can scale care, from filtering patient data to managing population health. They share J.P. Morgan Healthcare Conference updates on why organizational trust, rather than just regulatory stamps, is the key to successful AI in healthcare. What You Will Discover: - What changed in the regulatory landscape? - How the shift affects clinician workflows - Who should pay for clinical data platforms? - JPM Conference Insights - The importance of governance and trust - Biologics, biosimilars, and China competition - Practical strategies for continuous learning Referenced in the show: 🖇️ "Supercharging a New FDA: Marty Makary on Science, Power & Patients" – https://www.youtube.com/watch?v=DBlOJpT9Y1Y 🖇️A Field Guide to Deploying AI Agents in Clinical Practice – https://mitsloan.mit.edu/shared/ods/documents?PublicationDocumentID=10789 Connect with us: Dr. Junaid Kalia, Neurocritical Care Specialist and Founder of Savelife.AI™ 💼LinkedIn - https://www.linkedin.com/in/junaidkaliamd 🔗Website - https://www.junaidkalia.com/ 📹YouTube - https://www.youtube.com/@junaidkaliamd 📑Substack - https://substack.com/@junaidkaliamd2025? Dr. Harvey Castro, ER Physician, #DrGPT™ 💼LinkedIn - https://www.linkedin.com/in/harveycastromd/ 🔗Website - https://www.harveycastromd.com/ 📷Instagram - https://www.instagram.com/harveycastromd/?hl=en 📑Substack - https://harveycastromd.substack.com/ Edward Marx, CEO, Advisor 💼LinkedIn - https://www.linkedin.com/in/edwardmarx/ 🔗Website - https://www.marxadvisory.com/ 📹YouTube - https://www.youtube.com/@EdwardMarx Visit our website: https://signalandsymptoms.com/ Get advisory insights about Healthcare AI — at zero cost: https://junaidkaliamd.substack.com/

Episode details come from the podcast's RSS feed.

Embed this episode

Ready to play

What FDA's Step Back Means in Building Credibility

0:00 19:15

No transcript yet.

Requests help us decide what to transcribe next.

Frequently asked questions

How long is this episode of Signal and Symptoms Podcast?

This episode is 19 minutes long.

When was this Signal and Symptoms Podcast episode published?

This episode was published on February 3, 2026.

Can I download this Signal and Symptoms Podcast episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.